[go: up one dir, main page]

AR065272A1 - Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas - Google Patents

Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas

Info

Publication number
AR065272A1
AR065272A1 ARP080100555A ARP080100555A AR065272A1 AR 065272 A1 AR065272 A1 AR 065272A1 AR P080100555 A ARP080100555 A AR P080100555A AR P080100555 A ARP080100555 A AR P080100555A AR 065272 A1 AR065272 A1 AR 065272A1
Authority
AR
Argentina
Prior art keywords
compound
thiazolidinodiona
same
manufacturing methods
crystal forms
Prior art date
Application number
ARP080100555A
Other languages
English (en)
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AR065272A1 publication Critical patent/AR065272A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una forma cristalina en base a un compuesto de tiazolidinodiona, que es efectivo como un ingrediente farmacéutico para fabricar un activador del receptor activado por el multiplicador de peroxisomas (PPAR)gamma, una composicion farmacéutica contra el cáncer; y un método de preparacion de la forma cristalina. La presente se refiere a una forma cristalina de un hidrato de diclorhidrato de 5-(4-{[6-(4-amino-3,5-dimetilfenoxi)-1-metil-1-H-bencimidazol-2-il]metoxi}bencil)-1,3-tiazolidino-2,4- diona, representado por la formula (1).
ARP080100555A 2007-02-08 2008-02-08 Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas AR065272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90025107P 2007-02-08 2007-02-08

Publications (1)

Publication Number Publication Date
AR065272A1 true AR065272A1 (es) 2009-05-27

Family

ID=39521789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100555A AR065272A1 (es) 2007-02-08 2008-02-08 Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas

Country Status (19)

Country Link
US (2) US8236834B2 (es)
EP (1) EP2086971A1 (es)
JP (1) JP5748954B2 (es)
KR (1) KR20090107013A (es)
CN (1) CN101578283B (es)
AR (1) AR065272A1 (es)
AU (1) AU2008215384B2 (es)
BR (1) BRPI0805830A2 (es)
CA (2) CA2728541C (es)
IL (1) IL197825A0 (es)
MX (1) MX2009003535A (es)
NZ (1) NZ575786A (es)
PE (1) PE20090647A1 (es)
PH (1) PH12012501776A1 (es)
RU (1) RU2414470C2 (es)
SG (1) SG193039A1 (es)
TW (2) TW200838512A (es)
WO (1) WO2008099944A1 (es)
ZA (1) ZA200902354B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
EP2311834A4 (en) * 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
US20110124692A1 (en) * 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
US8420819B2 (en) * 2009-06-03 2013-04-16 Boehringer Ingelheim International Gmbh Process for optimizing the particle size of an active pharmaceutical ingredient by crystallization
CA2781800A1 (en) 2009-11-26 2011-06-03 Daiichi Sankyo Company, Limited Method for manufacturing a 6-substituted 1-methyl-1h-benzimidazole derivative and an intermediate of said method
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255386C (zh) * 1997-10-08 2006-05-10 三共株式会社 有取代稠合杂环化合物
JP3488099B2 (ja) * 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
HK1039940B (en) 1999-04-07 2010-08-27 Sankyo Company, Limited Amine derivatives
JP4169450B2 (ja) * 1999-04-07 2008-10-22 第一三共株式会社 インスリン抵抗性改善剤
EP1277753A1 (en) * 1999-04-23 2003-01-22 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
AU4882801A (en) 2000-04-25 2001-11-07 Kyorin Pharmaceutical Co. Ltd. Novel stable crystal of thiazolidinedione derivative and process for producing the same
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
WO2003053440A1 (en) * 2001-12-11 2003-07-03 Sankyo Company, Limited Medicinal composition
JP2004083574A (ja) 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
AU2003246187A1 (en) * 2002-06-25 2004-01-06 Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING DIURETIC AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) Gamma ACTIAVTOR
JP2004075448A (ja) 2002-08-15 2004-03-11 Taiyo Yuden Co Ltd 圧電磁器組成物、圧電磁器組成物の製造方法および圧電セラミック部品
JP2005162727A (ja) * 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) * 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP4789180B2 (ja) * 2004-09-28 2011-10-12 第一三共株式会社 ６−置換−１−メチル−１−ｈ−ベンズイミダゾール誘導体の製造方法及びその製造中間体
CN102391203A (zh) 2004-09-28 2012-03-28 三共株式会社 制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
RU2419430C2 (ru) * 2006-02-09 2011-05-27 Дайити Санкио Компани, Лимитед Противораковая фармацевтическая композиция
US20110124692A1 (en) 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
EP2311834A4 (en) 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
PH12012501776A1 (en) 2014-04-28
MX2009003535A (es) 2009-05-11
ZA200902354B (en) 2010-03-31
JP5748954B2 (ja) 2015-07-15
US20120252854A1 (en) 2012-10-04
US20110046388A1 (en) 2011-02-24
AU2008215384B2 (en) 2011-06-23
KR20090107013A (ko) 2009-10-12
IL197825A0 (en) 2009-12-24
CN101578283B (zh) 2013-01-02
EP2086971A1 (en) 2009-08-12
CA2665048C (en) 2011-11-08
PE20090647A1 (es) 2009-05-29
SG193039A1 (en) 2013-09-30
TW200838512A (en) 2008-10-01
CN101578283A (zh) 2009-11-11
BRPI0805830A2 (pt) 2011-08-30
NZ575786A (en) 2011-05-27
JP2010517932A (ja) 2010-05-27
US20110213158A9 (en) 2011-09-01
WO2008099944A1 (en) 2008-08-21
RU2009115179A (ru) 2010-10-27
CA2728541C (en) 2013-04-02
US8552038B2 (en) 2013-10-08
AU2008215384A1 (en) 2008-08-21
AU2008215384A8 (en) 2009-06-11
US8236834B2 (en) 2012-08-07
RU2414470C2 (ru) 2011-03-20
TW201336497A (zh) 2013-09-16
CA2665048A1 (en) 2008-08-21
CA2728541A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
AR065272A1 (es) Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas
PE20120002A1 (es) Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
UY31244A1 (es) Profarmacos dipeptoides y su uso
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CL2023001222A1 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
AR067090A1 (es) Espiriciclos como inhibidores de la 11- beta hidroxiesteroide deshidrogenasa de tipo 1
PE20120812A1 (es) Compuestos vinil indazolilo
ECSP12011935A (es) Triazolopiridinas
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
CL2023001224A1 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación
DOP2014000133A (es) Triazolopiridinas sustituidas
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
UY29766A1 (es) Formas cristalinas delta y épsilon de mesilato de imatinib
MX2009010567A (es) Derivados de imidazolidinona.
ECSP12012338A (es) Triazolopiridinas sustituidas
WO2009021868A3 (en) Novel piperazine amide derivatives
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20091450A1 (es) INHIBIDORES DE LA ESTEAROIL-CoA-DESATURASA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal